A confluence of recent scientific evidence has illuminated how NRF2-driven transcriptional programs support cancer cell survival through tumor-intrinsic mechanisms and also sculpt the tumor immune microenvironment to suppress cytotoxic immune responses and dampen the efficacy of anti-PD1 checkpoint immunotherapy. Here, NFE2L2 is linked to neoplasm.